NPR1 Antibody

What is NPR1 and why are antibodies against it important for research?

In human systems, NPR1 (natriuretic peptide receptor A/guanylate cyclase A) is a membrane-bound guanylate cyclase receptor involved in blood pressure regulation and cardiac function. This 119 kDa protein plays a critical role in cardiovascular homeostasis, and its dysregulation is associated with heart failure . In plants, NPR1 (nonexpresser of PR genes 1) functions as a key transcription coactivator essential for basal immunity and systemic acquired resistance (SAR) .

Antibodies targeting NPR1 are vital research tools for investigating cardiovascular disease mechanisms, particularly heart failure, in human studies. In plant biology, they help elucidate immune response pathways. The development of specialized antibodies like REGN5381, an investigational monoclonal agonist antibody, demonstrates the therapeutic potential of NPR1 targeting for conditions like heart failure .

What applications are NPR1 antibodies most commonly used for?

NPR1 antibodies have demonstrated utility across multiple experimental applications:

For Western blot applications in plant research, more concentrated antibody solutions (approximately 1:1000) may be required for optimal detection of the 66 kDa plant NPR1 protein . Human NPR1 typically appears at approximately 119 kDa in Western blot analyses .

How should NPR1 antibodies be stored and handled to maintain effectiveness?

Proper storage and handling are crucial for maintaining antibody activity:

For polyclonal antibodies like Anti-NPR1 (AS12 1854-500), lyophilized antibodies should be stored at -20°C, and once reconstituted, aliquoting is recommended to avoid repeated freeze-thaw cycles . Reconstitution typically requires adding a small volume (e.g., 50 μl) of sterile water to each tube .

For commercial antibodies like the Proteintech NPR1 antibody (55116-1-AP), storage in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 is recommended. These can be kept at -20°C and remain stable for one year after shipment, with aliquoting being unnecessary for -20°C storage .

Always remember to briefly spin tubes before opening to avoid material loss adhering to the cap or tube sides .

How can I optimize protein extraction protocols for enhanced NPR1 detection?

Effective NPR1 detection requires optimized protein extraction protocols tailored to your research model:

For plant samples (e.g., Arabidopsis thaliana), collecting leaf tissue (approximately 0.2g from 3-week-old rosettes) 24 hours after treatment (e.g., with 0.5 mM sodium salicylate spray) is effective. Extract total protein in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.1% Triton X-100, 0.2% nonidet P-40, and 50 μM MG115 (proteasome inhibitor) .

For human samples, standard RIPA buffer protocols can be used, but adding protease inhibitors is essential as NPR1 can be subject to degradation. When working with membrane-bound human NPR1, inclusion of appropriate detergents in extraction buffers is crucial for efficient solubilization .

Regardless of source, sample denaturation should be performed with SDS sample buffer containing adequate reducing agents (e.g., 50 mM DTT final concentration) at moderate temperature (e.g., 75°C for 15 minutes) to preserve epitope integrity while ensuring complete denaturation .

What are the key validation steps to ensure NPR1 antibody specificity in experimental systems?

Antibody validation is crucial for ensuring experimental reliability:

• Knockout/knockdown controls: Use NPR1 knockout or knockdown samples alongside wildtype samples. The 55116-1-AP antibody has been validated in KD/KO systems according to publications .

• Mutant analysis: When working with plant NPR1, consider using known mutants like npr1-3 (a potential null mutant) rather than npr1-1 (which is not a complete null) .

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application to demonstrate binding specificity.

• Cross-reactivity assessment: For plant NPR1 antibodies, test against multiple species. For example, the AS12 1854-500 antibody shows confirmed reactivity with Arabidopsis thaliana but is not reactive with Nicotiana benthamiana, Nicotiana tabacum, Solanum lycopersicum, or Solanum tuberosum .

• Multiple detection methods: Validate findings using orthogonal approaches (e.g., mass spectrometry) to confirm antibody specificity.

What are the recommended sample preparation procedures for Western blot analysis of NPR1?

For optimal Western blot detection of NPR1:

For plant samples, adjust protein samples to equal total protein concentration and denature with 4X SDS Sample buffer containing 200 mM DTT (final sample concentration of 50 mM) at 75°C for 15 minutes. Separate protein samples (approximately 30 μg of total protein) on 4-12% Bis-Tris gels and transfer to PVDF membranes using semi-dry transfer systems. Block membranes with 1X PBS-T containing 5% low-fat dry milk and 0.1% Tween-20 for 1 hour at room temperature with agitation. Incubate with primary antibody (diluted 1:1000 in blocking solution) overnight at 4°C with agitation .

For human NPR1 detection, similar protocols apply, but the expected molecular weight is 119 kDa rather than 66 kDa observed in plant samples . Ensure adequate separation of high molecular weight proteins by using lower percentage gels or gradient gels with appropriate resolution in the 100-120 kDa range.

How do NPR1 agonist antibodies like REGN5381 differ from standard detection antibodies in application and interpretation?

Agonist antibodies like REGN5381 represent a fundamentally different application of antibody technology compared to standard detection antibodies:

REGN5381 is an investigational human immunoglobulin G4-based monoclonal antibody designed to bind to and directly activate NPR1, functioning as an allosteric agonist that induces an active-like receptor conformation . Unlike detection antibodies, REGN5381 has therapeutic potential, producing hemodynamic effects preferentially on venous vasculature, including reductions in systolic blood pressure and venous pressure in animal models .

When using agonist antibodies in research:

• Focus on functional readouts (e.g., cGMP production, blood pressure changes) rather than just binding

• Consider using humanized animal models, as REGN5381 is selective for human NPR1 and does not bind to mouse NPR1 protein

• Evaluate both in vitro activation (using techniques like Ca²⁺ signaling assays) and in vivo physiological effects

• Assess antibody effects in the presence and absence of endogenous ligands to understand potential synergistic or competitive interactions

The interpretation of results should focus on functional outcomes rather than simple detection of the target protein.

What methodological differences should be considered when studying NPR1 in plant versus human research contexts?

The dual nature of NPR1 across plant and human systems necessitates distinct methodological approaches:

Plant NPR1 research methodologies:

• Focus on nuclear localization and protein-protein interactions with TGA transcription factors

• Consider induction treatments with salicylic acid or pathogen challenge

• Expected molecular weight is approximately 66 kDa

• Key mutants include npr1-1 (not a complete null) and npr1-3 (potential null mutant)

• Quantitative PCR methods are often employed to measure NPR1 transcript levels in response to treatments

Human NPR1 research methodologies:

• Focus on membrane localization and guanylate cyclase activity

• Functional assays measuring cGMP production are critical

• Expected molecular weight is approximately 119 kDa

• Consider examining both genetic variants (LOF vs. GOF) and their association with biomarkers like NT-proBNP

• Structural biology approaches (e.g., cryo-EM) may be employed to understand antibody binding and receptor conformational changes

When planning experiments, these fundamental biological differences must guide methodology selection, control design, and result interpretation.

How does NPR1 expression level influence experimental design and antibody selection?

NPR1 expression dynamics significantly impact experimental design considerations:

In plant systems, NPR1 transcript levels increase two- to threefold upon pathogen infection or salicylic acid treatment . This induction is regulated by TGA factors, though the reverse TGA box in the 5'UTR of NPR1 is dispensable for induction . Full induction of NPR1 is required for basal immunity but not for systemic acquired resistance (SAR), whereas sufficient basal transcription is essential for full-scale establishment of SAR .

For human NPR1, expression levels may vary across tissues and disease states. Individuals carrying protein-truncating variants (presumed loss-of-function) of NPR1 tend to have higher blood pressure and higher NT-proBNP than non-carriers .

These expression dynamics should inform:

• Timing of sample collection (e.g., post-induction in plant systems)

• Selection of antibody concentrations and detection methods appropriate for baseline vs. induced expression levels

• Inclusion of appropriate controls to account for expression variability

• Consideration of genetic background when studying human samples

What are the critical considerations when designing experiments to study NPR1-related protein-protein interactions?

NPR1 functions through complex protein interactions, requiring specialized experimental approaches:

For plant NPR1, consider:

• NPR1 interacts with TGA transcription factors in the nucleus

• Protein extraction methods must preserve these interactions if studying them (non-denaturing conditions)

• Co-immunoprecipitation with anti-NPR1 antibodies can help identify interaction partners

• Subcellular fractionation may be necessary to examine nuclear vs. cytoplasmic interactions

For human NPR1 (guanylate cyclase receptor):

• REGN5381 binding studies reveal important structural insights, including the finding that more than one REGN5381 IgG can bind to an NPR1 dimer, but both Fab arms of a single REGN5381 antibody are unable to bind to a single NPR1 dimer

• Advanced techniques like asymmetric flow field-flow fractionation coupled to multi-angle light scattering (A4F-MALS) can provide crucial data on antibody-receptor interactions

• Cryo-EM analysis shows minimal conformational changes in NPR1 structure upon REGN5381 binding, with only two residues (Pro42 and Gly43) shifting by more than 2 Å

When designing such experiments, consider the native oligomeric state of NPR1 (dimeric for human NPR1), the potential for conformational changes upon binding, and the appropriate buffer conditions to maintain functional protein interactions.

What are common challenges in NPR1 detection and how can they be overcome?

Researchers frequently encounter several challenges when working with NPR1 antibodies:

High background signal:

• Increase blocking stringency (5% BSA or milk)

• Try alternative blocking buffers

• Increase wash duration and number of washes

• Titrate antibody concentration to determine optimal dilution

Weak or no signal:

• Ensure sample preparation preserves epitope integrity

• Try different extraction buffers and conditions

• Consider sample enrichment techniques for low abundance targets

• For plant NPR1, induction with salicylic acid may be necessary to achieve detectable levels

• Verify protein transfer efficiency in Western blots

Multiple bands or unexpected molecular weights:

• For plant NPR1, the expected molecular weight is 66 kDa

• For human NPR1, the expected molecular weight is 119 kDa

• Additional bands may represent post-translational modifications, degradation products, or splice variants

• Validate with additional antibodies or detection methods

Variability between experiments:

• Standardize protein extraction methods

• Include positive controls in each experiment

• Normalize to housekeeping proteins

• Maintain consistent antibody lots when possible

How should researchers interpret NPR1 mutant studies in the context of antibody-based experiments?

Understanding NPR1 mutants is crucial for proper experimental design and interpretation:

In plant research, two mutant alleles, npr1-1 and npr1-3, have been extensively used. Recent research indicates that npr1-3 is a potential null mutant, whereas npr1-1 is not a complete null . This distinction has important implications for experimental design and interpretation. When selecting negative controls for antibody validation, npr1-3 would be preferable as it represents a more complete loss of function .

The research also demonstrates that truncated npr1 proteins longer than the hypothesized npr1-3 protein are not active in salicylic acid signaling . This information helps interpret potential cross-reactive bands that might appear in Western blots when using NPR1 antibodies.

For human NPR1 research, understanding the impact of loss-of-function (LOF) versus gain-of-function (GOF) variants provides context for interpreting experimental results. The burden of blood pressure-increasing presumed-LOF variants is associated with higher NT-proBNP and increased odds of heart failure, whereas the burden of blood pressure-lowering presumed-GOF variants is associated with lower NT-proBNP and numerically lower odds of heart failure .

How might agonist antibodies like REGN5381 inform future therapeutic approaches for heart failure?

REGN5381 represents a promising new approach to heart failure treatment:

Heart failure is a leading cause of morbidity and mortality, and NPR1 gene variants are associated with changes in blood pressure and heart failure risk . REGN5381, as an allosteric agonist of NPR1, induces an active-like receptor conformation that results in hemodynamic effects preferentially on venous vasculature .

In healthy human volunteers, REGN5381 produced expected hemodynamic effects reflecting reductions in venous pressures without obvious changes in diuresis and natriuresis . This selective venous pressure reduction may offer advantages over current therapies.

Future research directions include:

• Long-term efficacy and safety studies in heart failure patients

• Comparison with existing heart failure therapies

• Combination approaches with established treatments

• Identification of patient subgroups most likely to benefit based on NPR1 genetic variants

• Development of biomarkers to predict and monitor treatment response

The data supporting REGN5381's development highlights the beneficial role of long-term agonism of NPR1 in heart failure settings and suggests a new therapeutic paradigm for selective and durable venous pressure reduction .

What emerging methodologies might enhance NPR1 research in both plant and human systems?

Several cutting-edge approaches are poised to advance NPR1 research:

Advanced structural biology:

• Cryo-EM has already provided insights into NPR1-antibody interactions

• Further structural studies may reveal additional binding sites and conformational changes

• Molecular dynamics simulations could predict functional outcomes of binding events

Genomic and genetic approaches:

• CRISPR/Cas9-mediated gene editing for creating precise NPR1 variants

• Single-cell transcriptomics to understand cell-specific NPR1 expression patterns

• Genetic association studies to connect NPR1 variants with disease outcomes

Novel antibody technologies:

• Bi-specific antibodies targeting NPR1 and complementary pathways

• Antibody fragments with enhanced tissue penetration

• Intrabodies for targeting intracellular plant NPR1

Advanced imaging:

• Super-resolution microscopy for visualizing NPR1 dynamics in living cells

• Multiplexed imaging to simultaneously track NPR1 and interaction partners

• Intravital imaging to monitor NPR1 activity in intact tissues

These emerging methodologies promise to deepen our understanding of NPR1 biology and accelerate the development of targeted therapeutics for cardiovascular disease as well as enhance our knowledge of plant immune responses.